secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organogenesis Holdings Inc. (ORGO)
CIK:        0001661181
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-056885
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organogenesis beats Q1 revenue guidance with $110.0M; net loss narrows to $2.1M
-------------------------------------------------------------------------------

- Net revenue $110.0M, up 2% YoY, exceeding high-end of FY2024 guidance.
- Advanced Wound Care revenue $103.9M (+3%); Surgical & Sports Medicine $6.1M (-9%).
- GAAP net loss $2.1M ($0.02 EPS); adjusted net loss $1.4M; Adjusted EBITDA $2.6M.
- FY2024 guidance reaffirmed: revenue $445M-$470M; adjusted EBITDA $15.8M-$35M.
- Cash $89.3M, debt $64.9M as of March 31, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661181/000095017024056885/0000950170-24-056885-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661181/000095017024056885/orgo-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-056885

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer